Figure 1. Ten chemotherapeutic drugs induce the bacterial SOS response

Slides:

Advertisements

Similar presentations

Figure 6. RRs for clinical cure rates stratified by different diseases

Advertisements

Figure 1. Distribution of ABCB1 SNVs and haplotypes.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 1 Data-selection process

Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1. Colistin MIC distribution for the 153 colistin-resistant E

Figure 1. Variation in population size of the donor strain HN-1 and E

Figure 1 Phases of the research. Author’s own work.

Figure 1. Linkage analyses of the SNPs in the MRE11 gene and haplotype blocks. Haplotype blocks were defined for all ... Figure 1. Linkage analyses of.

Figure 1. Structure of two poxtA-carrying plasmids in E

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Fig. 1 CT demonstrating aortic wall thickening with renal artery involvement (short arrow). There is also subtle ... Fig. 1 CT demonstrating aortic wall.

Figure 1. SpeI-PFGE dendrogram comparing P

bDMARD: biologic DMARD.

Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.

Fig. 1 MRI aspect of an osteitis of the left acetabulum at baseline (A), 3 months (B), 1 year (C) and 2 years later, ... Fig. 1 MRI aspect of an osteitis.

Figure 1. Uptake of relebactam into human OAT1, OAT3 and OCT2 stably transfected cells. Time-dependent uptake of ... Figure 1. Uptake of relebactam into.

Take home figure The protective role of CNP/NPR-B/NPRC.

Fig. 3 Interrelationship between themes describing the experiences of people with shoulder disorders Unless provided in the caption above, the following.

x-axis, post-partum days. Closed ...

Fig. 1. A flowchart of cohort participants screened, enrolled and followed-up between 1 July 2015 and 31 May Fig. 1. A flowchart of cohort participants.

Fig. 1 Subacute cutaneous lupus erythematous at the lower limbs

Fig. 1 Flow chart of included patients for analyses

Figure 1. Mean log10 cfu/mL versus time profile for each individual drug at 4× MIC against the four VRE ... Figure 1. Mean log10 cfu/mL versus.

Fig. 1 Flow chart for selection of study subjects

Figure 1. Susceptibility of all P

Figure 1. (a) Geographical representation of sample collection area

Prevalence and distribution of ...

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Relationships between pair indices of dance performance (joint entropy or mutual information) and the past ... Figure 1 Relationships between.

Figure 1. Flow diagram for selection of articles for systematic review. Unless provided in the caption above, the following copyright applies to the content.

Figure 1. Sequence comparison of plasmid pG38 (GenBank accession no

Figure 1. Time–kill studies for selected isolates (each line represents the average of duplicate studies). AMP, ... Figure 1. Time–kill studies for selected.

Figure 1. Percentage of Pacific and European children completing all components of B4SC in 2013 and 2015 Figure 1. Percentage of Pacific and European.

Figure 1 MIC test strips showing reversion of daptomycin resistance of isolate 5 passaged in vitro. This figure ... Figure 1 MIC test strips showing reversion.

Figure 1. Outer membrane protein profiling of parental strain KJΔDEFΔ5 and its derivative fluoroquinolone-resistant ... Figure 1. Outer membrane protein.

Figure 1. Trunk and leg fat over study period. LS, log transformed.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Take home figure Proposed mechanisms of Staphylococcus aureus endocarditis. CVC, central venous catheter; IV, intravenous; S. ... Take home figure Proposed.

Fig. 1 Kaplan-Meier plot presenting no difference in progression to RA in patients with clinically suspect ... Fig. 1 Kaplan-Meier plot presenting no difference.

Figure 1. Colony morphology of an A. fumigatus non-WT strain and an A

Figure 1. The unique structures of the SCCmec type II element identified in ORSL strain CGMH-SL Figure 1. The unique structures of the SCCmec type.

Figure 1. Oncoprint of selected pathogenic alterations detected in ctDNA. Unless provided in the caption above, the following copyright applies to the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 1. Observed mean (SD) micafungin plasma concentrations.

Figure 2. (a) Geometric mean (%CV) tenofovir diphosphate concentrations (TFV-DP in fmol/punch) in dried blood spot ... Figure 2. (a) Geometric mean (%CV)

Figure 1. Biofilm susceptibility to antibiotic treatment

Figure 1. Time–kill curves of M. abscessus CIP

Fig. 1 A network representation of top 100 co-occurring terms

Figure 1. Genetic context of blaNDM-21 on pNDM21_020023

Fig. 1 Statistics of the main characters’ dialogues.

Figure 1 Patient selection.

The figure shows the fraction of ...

Figure 1 Grant agencies and charitable foundations supporting Plan S.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Fig. 1 Schematic subcategorization of AAV in three clinically relevant disease categories defined by clinical ... Fig. 1 Schematic subcategorization of.

Figure 1. Percentage of samples with MDR (a), phenotypic ESBL-producing (b), fluoroquinolone-resistant (c) and ... Figure 1. Percentage of samples with.

Figure 1. CCG and practice decile and extreme percentile (1–9, 91–99) time trends, 2011–17. This figure appears in ... Figure 1. CCG and practice decile.

Figure 1 Strategies for reconciling protection and participation.

Figure 1 ABCDE of primary prevention.2

Figure 1. Forest plot of lung cancer mortality in LDCT trials.

Table 2. Mean noise level results for hand dryers in dBA

Figure 1. Overall response rates in wild-type versus RAS and RAS/BRAF mutations detected by nanofluidic digital PCR ... Figure 1. Overall response rates.

Figure 1. Kaplan–Meier curves showing the impact of the different pretreatment HIV-1 drug resistance categories on the ... Figure 1. Kaplan–Meier curves.

Presentation transcript:

Figure 1. Ten chemotherapeutic drugs induce the bacterial SOS response Figure 1. Ten chemotherapeutic drugs induce the bacterial SOS response. (a) Classification of the 39 compounds tested. ... Figure 1. Ten chemotherapeutic drugs induce the bacterial SOS response. (a) Classification of the 39 compounds tested. (b) The first column shows the result of the screening of SOS-response induction in E. coli WT (black box, positive; light grey box, negative). The second column shows the intensity of the induction, which is the ratio of the mean fluorescence of E. coli WT induced (at the concentration shown in the third column) by a chemotherapeutic drug versus those that were not. n ≥ 3; two-sided Student’s t-tests using 1.0 as comparator. The fourth column shows the drug concentrations used for experiments with pathogenic species. The fifth column shows the range of therapeutic concentrations, retrieved from the literature (Table 1). The monoclonal antibody trastuzumab was used as a negative control (data not shown). Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) J Antimicrob Chemother, dkz070, https://doi.org/10.1093/jac/dkz070 The content of this slide may be subject to copyright: please see the slide notes for details.

Figure 2. Eight chemotherapeutic drugs enhance the frequency of mutation in E. coli, mostly through the activation of ... Figure 2. Eight chemotherapeutic drugs enhance the frequency of mutation in E. coli, mostly through the activation of the SOS response. The frequency of emergence of rifampicin-resistant mutants is shown from E. coli WT and E. coli ΔSOS after induction with chemotherapeutic drugs at therapeutic concentrations (from Figure 1b). Ratios of the geometric means of the frequency of resistant mutants with error bars representing the 95% CI are shown. n ≥ 3; two-sided Student’s t-tests using 1.0 (broken line) as comparator. The monoclonal antibody trastuzumab was used as a negative control (data not shown). Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) J Antimicrob Chemother, dkz070, https://doi.org/10.1093/jac/dkz070 The content of this slide may be subject to copyright: please see the slide notes for details.

Figure 3. Therapeutic concentrations of dacarbazine, azacitidine and streptozotocin enhance the emergence of ... Figure 3. Therapeutic concentrations of dacarbazine, azacitidine and streptozotocin enhance the emergence of antibiotic-resistant mutants of bacterial pathogens. The value shown on the y-axis is the ratio of the frequencies of emergence of imipenem-resistant P. aeruginosa, ciprofloxacin-resistant S. aureus and cefotaxime-resistant E. cloacae, with and without induction with chemotherapeutic drugs at the concentrations given in Figure 1(b). Ratios of the geometric means of the frequency of resistant mutants with error bars representing the 95% CI are shown. n ≥ 3; two-sided Student’s t-tests using 1.0 (broken line) as comparator. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) J Antimicrob Chemother, dkz070, https://doi.org/10.1093/jac/dkz070 The content of this slide may be subject to copyright: please see the slide notes for details.